ELVN Enliven Therapeutics, Inc.

NEUTRAL Impact: 2/10 144
Horizon days Filed Jun 5, 2026 Processed 7d 12h ago SEC 0001974158-26-000072
Form 144 — notice of proposed sale of securities

Price Chart

Loading chart...

Executive Summary

Board member Lori Anne Kunkel filed a Form 144 notice of intent to sell 20,000 shares of Enliven Therapeutics (ELVN), with an estimated aggregate market value of $709,800. The sale is planned under a Rule 10b5-1 trading plan adopted on March 6, 2026, indicating the insider established the plan months before this filing and is not acting on recent material non-public information. Given the small relative size of the proposed sale (approximately 0.03% of the $2.2B market cap) and the pre-planned nature, this filing is routine and unlikely to materially impact the stock.

Actionable Insight

The Form 144 is a routine advance notice of a planned insider sale under a pre-existing 10b5-1 plan. No material impact expected. Monitor for actual execution on Form 4, but the small size and pre-planned nature suggest no negative signal. The stock's strong analyst consensus (94% bullish) and positive historical drift (+12.2% at T+20 on prior reports) support a neutral read-through.

Key Facts

  • Board member Lori Anne Kunkel filed Form 144 to sell 20,000 shares of ELVN common stock.
  • Estimated aggregate market value of the proposed sale is $709,800.
  • Sale is to be executed under a Rule 10b5-1 trading plan adopted on March 6, 2026.
  • Shares were acquired pre-IPO on March 12, 2020, as 'Pre-IPO Shares'.
  • Proposed sale represents approximately 0.03% of ELVN's $2.2B market cap.

Financial Impact

Proposed sale of 20,000 shares worth approximately $709,800, representing a small fraction of the company's $2.2B market cap.

dilution

Risk Factors

  • Insider sale could be perceived negatively by retail investors despite the 10b5-1 plan.
  • If the company's stock price weakens ahead of the sale, the plan may still execute, adding modest sell pressure.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
94% bullish (16 analysts)

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001974158-26-000072
Document: 0001974158-26-000072-index.html0001974158-26-000072
Document: 0001974158-26-000072.txt0001974158-26-000072
3 reports for ELVN
Performance horizon
Filters
Rows
Reports for ELVN — sortable, filterable
Type Now
Jun 12, 2026
today
424B5
BEARISH ★ 6/10
$46.12 awaiting T+20awaiting T+20$46.13 (−0.02%)
Jun 11, 2026
1d ago
8-K
BULLISH ★ 7/10
$38.00 awaiting T+20awaiting T+20$46.13 (+21.39%)
Jun 5, 2026
7d ago
144
NEUTRAL ★ 2/10
$35.44 awaiting T+20awaiting T+20$46.13 (+30.16%)
Showing 3 of 3

US Market Status

Market Closed — Opens Mon (52h 13m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access